Phase 2 Trial Oral Enzastaurin in Prostate Cancer Patients Who Have Rising PSA (1) During Hormonal Manipulation and (2) After First-Line Cytotoxic Chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2011
At a glance
- Drugs Enzastaurin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 10 Jun 2017 Biomarkers information updated
- 01 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Feb 2010 Planned end date changed from 1 Feb 2010 to 1 Oct 2010 as reported by ClinicalTrials.gov.